I presented our recent study entitled "Randomized,
controlled, crossover trial comparing the impact of sham or intranasal
neurostimulation on conjunctival goblet cell degranulation" at ARVO
meeting in Seattle. The research topic received a great deal of
attention amongst the scientists during the poster session.
Briefly, our results have documented that the
Oculeve Intranasal Lacrimal Neurostimulator (Allergan plc, Dublin,
Ireland.) not only increases aqueous tear production, it also stimulates
conjunctival goblet cell mucin secretion, offering a promising new approach to
treatment of dry eye.
I'd like to thank Prof. Stephen C. Pflugfelder
(Professor of Ophthalmology at Baylor College of Medicine, Houston, Texas, USA)
and Michael Ackermann (Vice President Neurostimulation at Allergan) for inviting me
to investigate this brand-new innovative product that will change the
management of dry eye.
Sincerely,
Koray Gumus, MD,
FEBOphth
Hiç yorum yok:
Yorum Gönder